DABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY

The widespread use of new oral anticoagulants in clinical practice requires improving the safety of medication use, i.e. the use of specific reversal agents, if necessary. Idarucizumab, a humanied monoclonal antibody fragment, is the first reversal agent authorized in our country that binds to dabig...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: N. A. Novikova, A. N. Volovchenko, D. A. Parfenov
Format: Artigo
Langue:Russo
Publié: «REMEDIUM GROUP» Ltd. 2019-06-01
Collection:Атеротромбоз
Sujets:
atrial fibrillation
dabigatran
idarucizumab
Accès en ligne:https://www.aterotromboz.ru/jour/article/view/183
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires